ORAL RU 28965 IN RESPIRATORY INFECTIONS

We carried out a study on the clinical efficacy and safety of RU 28965. In total, eleven patients with respiratory infections (pneuthonia 4, bronchiectasis 4, acute bronchitis 2, and chronic bronchitis 1) were treated with oral RU 28965 in a daily dose of 300-400 mg for 4-24 days. Clinical efficacy...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 36; no. Supplement4; pp. 306 - 310
Main Authors SATOH, TOSHINOBU, KUDO, KOICHIRO, KABE, JUNZABURO, YOSHIMOTO, KEIKO, KOWADA, AKIKO
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1988
公益社団法人 日本化学療法学会
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.36.Supplement4_306

Cover

More Information
Summary:We carried out a study on the clinical efficacy and safety of RU 28965. In total, eleven patients with respiratory infections (pneuthonia 4, bronchiectasis 4, acute bronchitis 2, and chronic bronchitis 1) were treated with oral RU 28965 in a daily dose of 300-400 mg for 4-24 days. Clinical efficacy was good in 5 cases, fair in 5 and poor in 1, with an overall clinical efficacy rate of 45.5%. Four strains of H. influenzae were isolated from sputum. Two strains were eradicated and the rest were unchanged after the treatment. Neither clinical side-effects nor abnormal laboratory findings were observed.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.36.Supplement4_306